{php}echo $_SESSION['the_Crumb'];{/php}

Bioscience Healthcare and Technology

Our corporate, IP and commercial technology groups frequently combine to offer sector-specific advice to the bioscience and healthcare sectors.

We provide investment, dispute resolution and commercial advice to a range of spin-out companies, multi-nationals and investors involved in the lifesciences industry.

We also handle transactions on behalf of technology and service providers to the health sector, as well as advising public sector healthcare bodies on strategic technology procurement issues.

Key areas of our expertise include:

M&A: We advise on both acquisition and divestment
IP: We advise on the protection, enforcement and exploitation of patents, know-how and all other IPR
Commercial arrangements, including R&D collaborations, pipe-line agreements, licensing and strategic alliances
Venture Capital: advising both capital providers and investee companies in the life sciences and healthcare sectors
Software & services: We act for suppliers and customers in the lifesciences and healthcare sectors on technology development, licensing, services and supply arrangements
Procurement: We advise on regulated tendering processes under the EU/GATT procurement rules. Our clients include public sector bodies as well as service providers participating in competitive procurement exercises, at both prime and sub contractor level
Data protection and regulatory advice: We advise on a wide range of regulatory issues regarding the handling of patient health records and other data and information

Our recent experience includes:

Advising a US pharmaceutical company on UK strategic acquisitions
Acting for large US based healthcare software and services company on acquisition of a services business from UK listed entity, and on a range of technology supply contracts with units of NHS
Acting for Microsoft on contractual matters relating to the NHS National Programme
Acting for private equity (debt and equity) backed healthcare company on the full range of its corporate, venturing and IT commercial activities and for its management team on exit

Back to Services